Company: MIRA
Filing Date: 2025-06-17
Form Type: PREM14A
Source: 0001641172-25-015340
Chunk: 178

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-06-17
Form: PREM14A
Chunk 178
---
CF as it enables conducting pharma and biotech valuation based on the stage (preclinical, Phase 1-3) of development of assets.

As mentioned in the company description, SKNY is currently in the process of developing two indications:

| ● | SKNY-1                                                    
 -Aims to treat Nicotine dependence and Smoking cessation. |

| ● | SKNY-1                        
 – As a Weight loss treatment. |

We have valued SKNY under the assumption that these are its only two projects. Therefore, we accounted for expected income and expenses related to these indications alone and did not take into consideration developments that the Company might be performing in the future.

Another assumption made for the sake of the current valuation is that the Company will develop the two indications on its own until the successful termination of the Phase II clinical trials and following that will seek for a business agreement with a large pharma company that will perform the Phase III clinical trials (on its own account) and after the successful conclusion of the trials will continue and market the finished products. SKNY will be entitled for an upfront payment at the end of Phase II and royalties from the third-party revenues.

| Moore Financial Consulting |

| SKNY Pharmaceuticals, Inc. | April 2025    |
| Valuation                  | Page 18 of 25 |

Timeline of the development of the Indications

Following, we present the assumptions regarding the development of the SKNY-1 for Nicotine Dependence and SKNY-1 for Weight Loss:

Based on information received from the company and our research, we have assumed the following regarding the development of SKNY-1 for both Indications:

The timeline is presented in the following chart:

*A single IND and Phase I are required for both SKNY-1 indications, and the costs are shared between the two indications.

Total Available Markets

SKNY-1 Nicotine Dependence

The total available market, therefore, comprises every case of smokers who use medication to quit smoking. We have assumed that the relevant markets for the Company in the first years of sales are as follows: U.S.A, Canada and Mexico. In the following table we present the prevalence in these markets:

| Moore Financial Consulting |

| SKNY Pharmaceuticals, Inc. | April 2025    |
| Valuation                  | Page 19 of 25 |

SKNY-1 Weight Loss

The total available market for this indication comprises Overweight (and obese) adults who use medication to lose weight. In the following table, we present the total available market